Tysabri is a type of disease modifying drug used in the treatment of certain forms of multiple sclerosis (MS). This medication works by preventing leukocytes from crossing the blood-brain barrier into the nervous system where they may exacerbate MS lesions. Tysabri is provided in concentrate form (300mg in 15 ml) for infusion.
What is it made of?
The ingredients in Tysabri include natalizumab (300mg), sodium chloride, sodium phosphate, polysorbate 80, and water for injections. The active ingredient, natalizumab, is a humanized antibody capable of selectively binding to the α4-subunit of human integrins, a component found on all leukocytes.
What are its uses?
Tysabri is prescribed to treat active relapsing remitting multiple sclerosis (MS), an autoimmune disease that affects the central nervous system. Treatment is given to lessen the severity and occurrences of MS relapses. This protein-based drug should only be prescribed to patients who did not respond well, or who is not suited, to first-line MS treatments. Tysabri is administered via intravenous infusion in a specialized infusion center by a health professional. The recommended dose of Tysabri is 300 mg every four weeks.
How long do its effects last?
Tysabri is intended as a long-term management tool of MS. Patients should not discontinue treatment on their own, as symptoms may reoccur.